TrialJournal for immunotherapy of cancer2021

Clinical and immunologic impact of short-course enzalutamide alone and with immunotherapy in non-metastatic castration sensitive prostate cancer.

Ravi A Madan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.